Targeted therapies for Kaposi sarcoma and KSHV-multicentric Castleman disease

$555,331ZIAFY2022CANIH

Division Of Basic Sciences - Nci

Investigators

Linked publications & trials

Paper 38941593 Paper 38564482 Paper 37756537 Paper 37715370 Paper 37578202 Paper 36632565 Paper 35876604 Paper 35848586 Paper 35803203 Paper 35102814 Paper 35080914 Paper 34890242 Paper 34862247 Paper 33989604 Paper 33720337 Paper 33273183 Paper 32276276

Abstract

Clinical projects - Established protocol of NHS-IL12/M7824 in Kaposi sarcoma open enrolment at the NCI KSHV-MCD protocol open enrolment at the NCI Abemaciclib in KS - open enrolment at the NCI Pacritinib in KSHV-MCD - Completed scientific review Gene expression patterns in GI and skin Kaposi sarcoma - 23 paired samples of gastrointestinal and cutaneous KS were obtained and analyzed with bulk RNA sequencing. Our analyses found that lytic KSHV genes were higher in GI samples. Of the host genes those that were clinically significant included FLT4, which encodes for a receptor of VEGF-C and VEGF-D. This data was presented as an oral abstract at the CROI 2022 meeting.

View original record on NIH RePORTER →